# An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer

> **NCT07315633** · — · RECRUITING · sponsor: **University Hospital, Ghent** · enrollment: 80 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Liver Cancer, Adult
- Liver Cancer

## Interventions

- **DEVICE:** Endovascular treatment

## Key facts

- **NCT ID:** NCT07315633
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2029-09-22
- **Final completion:** 2030-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07315633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07315633, "An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07315633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*